Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Short-term Investments: 2017-2025

Historic Short-term Investments for Protagonist Therapeutics (PTGX) over the last 9 years, with Sep 2025 value amounting to $462.4 million.

  • Protagonist Therapeutics' Short-term Investments rose 36.97% to $462.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $462.4 million, marking a year-over-year increase of 36.97%. This contributed to the annual value of $321.7 million for FY2024, which is 107.68% up from last year.
  • According to the latest figures from Q3 2025, Protagonist Therapeutics' Short-term Investments is $462.4 million, which was up 15.05% from $401.9 million recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year Short-term Investments high stood at $462.4 million for Q3 2025, and its period low was $225,000 during Q2 2021.
  • In the last 3 years, Protagonist Therapeutics' Short-term Investments had a median value of $208.4 million in 2024 and averaged $249.4 million.
  • In the last 5 years, Protagonist Therapeutics' Short-term Investments soared by 1,937,900.00% in 2021 and then tumbled by 54.56% in 2023.
  • Quarterly analysis of 5 years shows Protagonist Therapeutics' Short-term Investments stood at $203.2 million in 2021, then plummeted by 45.08% to $111.6 million in 2022, then spiked by 38.79% to $154.9 million in 2023, then spiked by 107.68% to $321.7 million in 2024, then skyrocketed by 36.97% to $462.4 million in 2025.
  • Its Short-term Investments stands at $462.4 million for Q3 2025, versus $401.9 million for Q2 2025 and $434.7 million for Q1 2025.